VivoSim Labs, Inc. (Nasdaq: VIVS) is a pharmaceutical and biotechnology services company that focuses on testing drugs and drug candidates in three-dimensional human tissue models of liver and intestine. This news page aggregates coverage of the company’s announcements, scientific presentations and corporate developments related to its NAMkind platform and toxicology services.
Readers can find updates on leadership changes, such as the appointment of a Chief Commercial Officer to guide go‑to‑market strategy and partnerships, and the appointment of a Chief Scientific Officer to oversee scientific strategy across toxicology, translational models, bioanalytics and next‑generation new approach methodologies. News items also highlight how VivoSim Labs combines organ‑specific 3D models with AI‑driven analytics to deliver what it describes as decision‑ready toxicology insights.
Company news includes reports of scientific results, such as presentations at conferences where VivoSim Labs has discussed the predictive performance of its NAMkind liver model against challenging liver toxicity cases. These articles describe sensitivity and specificity metrics within test sets of compounds and explain how the platform is intended to address unforeseen liver toxicity that can emerge in clinical trials or after market launch.
In addition, news releases from VivoSim Labs discuss its emergence from stealth mode, its focus on non‑animal NAM methods in the context of FDA initiatives to refine animal testing requirements, and its view of the market opportunity for liver and gastrointestinal in vitro models and toxicology services. Investors, scientists and industry professionals can use this page to follow how the company communicates its progress in AI‑enabled liver and intestine toxicology, regulatory context and corporate governance milestones over time.
VivoSim Labs (Nasdaq: VIVS) has emerged from stealth mode to revolutionize drug development with its NAMkind™ services suite, following FDA's announcement to phase out animal testing requirements. The company's technology focuses on liver and intestinal toxicology using human organ model-based lab testing and AI-powered computational modeling.
The company aims to disrupt the $10B+ animal testing market with more predictive and ethically sound methods. VivoSim's liver model has demonstrated industry-best correlation rates with known clinical failures, and the company projects it can reduce clinical trial failures due to liver toxicity by 50% or more.
The technology utilizes physical organoid wet lab models created from human donor cells, combined with AI-driven predictions for liver toxicity, intestinal toxicity, and permeability. VivoSim believes its approach could reduce drug development costs per approved drug by 50% across the industry.